RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Regenerative Medicine Advanced Therapy (United States), Advanced Therapy Medicinal Products (European Union), Rare Pediatric Disease (United States)

Clinical Trials associated with Deramiocel

NCT05126758

/ Active, not recruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

Start Date22 Jun 2022

Sponsor / Collaborator

Capricor, Inc.

NCT04623671

/ CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)

This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.

Start Date15 Nov 2020

Sponsor / Collaborator

Capricor, Inc.

NCT04428476

/ Active, not recruitingPhase 2

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial

This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months, over a period of approximately 60 months. Following completion of the initial open-label phase (Month 60), subjects who have completed all Month 60 assessments will be eligible to continue into a long-term open label extension (LT-OLE) period and can continue to receive deramiocel once every 3 months until deramiocel is commercially available or the sponsor terminates the study, or the subject withdraws consent or study participation is terminated by the sponsor.
Subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of deramiocel.
Subjects will complete trial assessments at Screening; Day 1; Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, and all LT-OLE visits. Safety and efficacy assessments will be conducted prior to deramiocel administration at the Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and at all LT-OLE trial visits, unless otherwise indicated.
All deramiocel infusions will be conducted in an outpatient setting at the investigative site on Day 1 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, with continued dosing in the LT-OLE visits. Subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site Investigator.

Start Date05 Aug 2020

Sponsor / Collaborator

Capricor, Inc.

100 Clinical Results associated with Deramiocel

100 Translational Medicine associated with Deramiocel

100 Patents (Medical) associated with Deramiocel

Literatures (Medical) associated with Deramiocel

01 Mar 2022·Lancet (London, England)Q1 · MEDICINE

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Q1 · MEDICINE

Article

Author: Omaid Sarwary ; Wendy Chouteau ; Siegfried Rogy ; Russell Butterfield ; Anne Connolly ; Alina Nicorici ; Michael D Taylor ; Arun S Varadhachary ; Cuixia Tian ; Joanne Janas ; Richard S Finkel ; Michelle Eagle ; Kyle Kusmik ; Sanjay Jhawar ; Kan N Hor ; Erica Goude ; Rebecca Rehborg ; Russell G. Rogers ; Erik K Henricson ; Angie Edmondson ; Suzanne Hendrix ; Anthony F. Giordano ; Linda Marbán ; Lauri Filar ; Julie Wells ; Pat Furlong ; Nathaniel Hogan ; Irina Rybalsky ; Eduardo Marbán ; Matthew M Harmelink ; Kristan Anderson ; Jayoon Baek ; Jorge Collado ; Maya Evans ; Francesco Muntoni ; Poonam Prasad ; Prasanth Surampudi ; Germaine Wezel ; Hannah Johnson ; Jennifer Van Eyk ; Aixa Rodriguez ; Melisa Vega ; Colleen Anthonisen ; Michelle Brown ; Rachel Ruckdeschel Smith ; Craig M McDonald ; Julie Duke ; Matthew Civitello ; Jonathan G. Dayan ; Oscar H Mayer ; Erika Pyzik ; Andrew Newton ; Nanette C. Joyce ; Mehrdad Abedi ; Deborah D Ascheim ; Paula Williams

BACKGROUND:

Cardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety and efficacy of sequential intravenous infusions of human allogeneic CDCs in late-stage Duchenne muscular dystrophy.

METHODS:

In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients with Duchenne muscular dystrophy, aged 10 years or older with moderate upper limb impairment, were enrolled at seven centres in the USA. Patients were randomly assigned (1:1) using stratified permuted blocks to receive CAP-1002 (1·5 × 10⁸ CDCs) or placebo intravenously every 3 months for a total of four infusions. Clinicians, caregivers, patients, and clinical operations personnel were fully masked to treatment groups. The primary outcome was the change in mid-level elbow Performance of Upper Limb version 1.2 (PUL 1.2) score at 12 months, assessed in the intention-to-treat population. Safety was assessed in all individuals who received an investigational product. This trial is registered with ClinicalTrials.gov, NCT03406780.

FINDINGS:

Between March 1, 2018, and March 31, 2020, 26 male patients with Duchenne muscular dystrophy were enrolled, of whom eight were randomly assigned to the CAP-1002 group and 12 to the placebo group (six were not randomised due to screening failure). In patients who had a post-treatment PUL 1.2 assessment (eight in the CAP-1002 group and 11 in the placebo group), the mean 12-month change from baseline in mid-level elbow PUL1.2 favoured CAP-1002 over placebo (percentile difference 36·2, 95% CI 12·7-59·7; difference of 2·6 points; p=0·014). Infusion-related hypersensitivity reactions without long-term sequelae were observed in three patients, with one patient discontinuing therapy due to a severe allergic reaction. No other major adverse reactions were noted, and no deaths occurred.

INTERPRETATION:

CAP-1002 cell therapy appears to be safe and effective in reducing deterioration of upper limb function in patients with late-stage Duchenne muscular dystrophy. Various measures of cardiac function and structure were also improved in the CAP-1002 group compared with the placebo group. Longer-term extension studies are needed to confirm the therapeutic durability and safety of CAP-1002 beyond 12 months for the treatment of skeletal myopathy and cardiomyopathy in Duchenne muscular dystrophy.

FUNDING:

Capricor Therapeutics.

01 Jul 2020·Basic research in cardiology

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Article

Author: Friedman, Oren ; Chen, Peter ; Marbán, Linda ; Singh, Siddharth ; Akhmerov, Akbarshakh ; Zaman, Tanzira ; Falk, Jeremy ; Ebinger, Joseph E ; Gheorghiu, Mitch ; Marbán, Eduardo ; Makkar, Raj R ; Chakravarty, Tarun

Abstract:

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19–75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43–2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89–1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26–0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23–1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.

19 Feb 2019·NeurologyQ1 · MEDICINE

Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial

Q1 · MEDICINE

Article

Author: Bharath Ambale-Venkatesh ; Ronald G. Victor ; Raj Makkar ; John Jefferies ; Bryan Goldstein ; Eduardo Marbán ; Linda Marbán ; James Fudge ; Joao Lima ; Barry Byrne ; Deborah D. Ascheim ; Rachel Ruckdeschel Smith ; Janice M. Pogoda ; Mohammad R. Ostovaneh ; Konstantinos Malliaras ; Michael Taylor ; Jeff Rudy ; Brian Fedor

OBJECTIVE:

To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD).

METHODS:

The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Participants were enrolled at 3 US medical centers between January and August 2016 and followed for 12 months. An independent Data and Safety Monitoring Board provided safety oversight. Cardiac function and structure were assessed by MRI, and analyzed by a blinded core laboratory. Skeletal muscle function was assessed by performance of the upper limb (PUL).

RESULTS:

Twenty-five eligible patients (mean age 17.8 years; 68% wheelchair-dependent) were randomized to CAP-1002 (n = 13) or control (n = 12). Incidence of treatment-emergent adverse events was similar between groups. Compared to baseline, MRI at 12 months revealed significant scar size reduction and improvement in inferior wall systolic thickening in CAP-1002 but not control patients. Mid-distal PUL improved at 12 months in 8 of 9 lower functioning CAP-1002 patients, and no controls (p = 0.007).

CONCLUSIONS:

Intracoronary CAP-1002 in DMD appears safe and demonstrates signals of efficacy on both cardiac and upper limb function for up to 12 months. Thus, future clinical research on CAP-1002 treatment of DMD cardiac and skeletal myopathies is warranted.

CLASSIFICATION OF EVIDENCE:

This phase I/II study provides Class II evidence that for patients with DMD, intracoronary CAP-1002 is feasible and appears safe and potentially effective.

229

News (Medical) associated with Deramiocel

26 Aug 2026

·www.biospace.com

Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed

FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart > Watch on YouTube Capricor Therapeutics has been trying to get its cell therapy for Duchenne muscular dystrophy across the finish line since last year, when it received its first rejection. The company resubmitted its application and the FDA accepted the application, with a PDUFA date this past weekend. That date came and went before the FDA granted a three-month extension . The extra time follows a contentious advisory committee meeting that could have implications for the broader industry . Meanwhile, Capricor has paused all other pipeline projects as it focuses on getting deramiocel across the regulatory finish line—a decision at least one shareholder is none too pleased with . Elsewhere, Moderna released promising Phase 3 results for its Merck-partnered personalized mRNA-based cancer vaccine, being trialed in combination with Keytruda for melanoma. The readout was highly anticipated and came ahead of schedule, nearly doubling Moderna’s stock the morning of the announcement. Merck will also benefit from continued good news around the program as it stares down the loss of Keytruda exclusivity. Over at the FDA, we finally have Trump’s next nominee for a permanent leader: White House aide Heidi Overton. Current Deputy Director of the White House Domestic Policy Council, Overton has a medical degree from the University of New Mexico, completed a surgical residency in general surgery at Johns Hopkins and has a PhD in clinical investigation from Hopkins’ Bloomberg School of Public Health. Analysts say she could be good for psychedelics and new pain meds but bad for vaccines. Finally, the oral obesity space is heating up as rivals Novo Nordisk and Eli Lilly fight for marketshare. Novo’s oral Wegovy has clearly outpaced Foundayo so far, a lead analysts have attributed in part to the drug’s name recognition. By contrast, Lilly’s pill is an entirely separate offering from its GLP-1 injectable Zepbound. Will Novo be able to retain its lead ? In one attempt to do so, the Danish pharma announced last week that it’s launching a Phase 3 study to determine an optimal lower starting dose of the Wegovy pill. Lilly, meanwhile, officially launched Foundayo in the U.K. this week—a market where analysts say the Indianapolis pharma may have an easier time thanks due to the high margins of a small-molecule therapy.” Novo’s Wegovy pill, by contrast, is a peptide that is harder and more expensive to manufacture. In the meantime, there are plenty of other companies hoping to break the Novo-Lilly weight loss duopoly. One of those with a pill—and a recent readout—is Enveda, which has been advertising its investigational asset as “ exercise in a tablet .”

Phase 3Clinical ResultVaccineCell Therapy

25 Aug 2026

·www.prnewswire.com

CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Aug. 25, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: . Key Details of the Capricor Therapeutics ($CAPR) Class Action: Lead Plaintiff Deadline: September 28, 2026 Lawsuit Allegations: Securities fraud alleging Capricor made false statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License Application. Largest Alleged Stock Drop: July 27, 2026 – 64.5% Stock Drop Court: U.S. District Court for the Southern District of California Action: Contact BFA Law to discuss your rights Investors have until September 28, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Capricor securities. The class action is pending in the U.S. District Court for the Southern District of California. It is captioned Nkamga v. Capricor Therapeutics, Inc. et al., No. 26-cv-04385. Why is Capricor Being Sued for Securities Fraud? Capricor is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an investigational cell therapy being developed for Duchenne muscular dystrophy. According to the complaint, Capricor submitted a Biologics License Application to the FDA for Deramiocel in late 2024. In July 2025, the FDA issued a Complete Response Letter stating that the application did not meet the statutory requirement for substantial evidence of effectiveness and that additional clinical data was needed. As alleged, Capricor failed to disclose that it adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel and that the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel BLA. Why did Capricor's Stock Drop? On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting concerning Deramiocel. The FDA briefing documents reportedly raised concerns about post-hoc changes to Capricor's statistical analysis plan, including changes to the methodology for calculating the primary endpoint, PUL 2.0, shortly before the database was unlocked and unblinded. This news caused the price of Capricor stock to decline $12.70 per share, or 64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per share on July 27, 2026, the following trading day. On July 29, 2026, the FDA advisory committee met to discuss the Deramiocel BLA. The next day, a medical news website named Medscape reported that in a non-binding 9-3 vote, the panel concluded that available evidence did not support the efficacy of Deramiocel for treating DMD-associated cardiomyopathy. On this news, Capricor's stock dropped $2.38 per share, or 36%, from a closing price of $6.57 per share on July 29, 2026, to $4.19 per share on July 30, 2026. Click here for more information: . What Can You Do? If you invested in Capricor Therapeutics securities, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit . Attorney advertising. Past results do not guarantee future outcomes. SOURCE Bleichmar Fonti & Auld LLP 21% more press release views with Request a Demo

Cell Therapy

25 Aug 2026

·www.fiercebiotech.com

Capricor secures reprieve as FDA extends DMD cell therapy review

The FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy (DMD) drug candidate, deferring the decision while the agency assesses information the biotech submitted after a negative advisory committee vote. The FDA was originally set to rule on the filing by Aug. 22, although investors’ hopes of approval had deflated after an advisory committee voted nine to three against the efficacy of the cell therapy. Capricor partly reinflated those hopes earlier this month by outlining plans to submit extra data and refocus its filing on a different endpoint. The FDA agreed to review the extra data, triggering a three-month extension. Capricor is now set to learn if the agency will approve its cell therapy candidate, deramiocel, by Nov. 22. Even so, investors continue to ascribe less value to Capricor than before the negative advisory committee vote, suggesting doubts about its chances of winning approval. The advisory committee discussion and briefing document the FDA prepared (PDF) for the meeting contain statements that support skeptical interpretations of Capricor’s chances. Capricor has shifted its submission from cardiomyopathy—the subject of the negative vote—to upper limb function. Because the advisory committee never voted on whether deramiocel improves upper limb function, the meeting delivered an inconclusive verdict on Capricor’s new indication. The advisory committee’s discussion of deramiocel’s effect on upper limb function “was directionally supportive of the clinical evidence,” Capricor CEO Linda Marbán, Ph.D., said on the company’s earnings call earlier this month. Yet multiple experts questioned the evidence on upper limb function, with one attendee saying that “it’s very hard to say that there is a real effect in terms of muscle strength.” Capricor’s revised submission contains clinical data that were unavailable to the advisory committee. Over the next three months, the FDA will assess whether the extra year of follow-up provided by Capricor, plus the original evidence, support approval. The agency raised concerns about the original evidence in its July briefing of the advisory committee. Capricor’s phase 3 trial failed to show a statistically significant or clinically meaningful effect on the pre-specified upper limb function endpoint, the FDA said. The biotech presented a statistically significant analysis of the primary endpoint, but the regulator concluded the results were hard to interpret.

100 Deals associated with Deramiocel

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscular Dystrophy, Duchenne	NDA/BLA	United States	Capricor Therapeutics, Inc.	10 Mar 2026
COVID-19	Phase 2	United States	Capricor, Inc.	15 Nov 2020
Heart failure with normal ejection fraction	Phase 2	United States	The Medical University of South Carolina	12 Jul 2017
Heart Failure, Diastolic	Phase 2	United States	The Medical University of South Carolina	12 Jul 2017
Cardiomyopathies	Phase 2	United States	Capricor, Inc.	07 Jan 2016
Tabes Dorsalis	Phase 2	United States	Capricor, Inc.	07 Jan 2016
Non-St Elevated Myocardial Infarction	Phase 2	United States	Capricor, Inc.	13 Nov 2012
ST Elevation Myocardial Infarction	Phase 2	United States	Capricor, Inc.	13 Nov 2012
Ventricular Dysfunction, Left	Phase 2	United States	Capricor, Inc.	13 Nov 2012
Cardiomyopathy, Dilated	Phase 1	United States	Capricor, Inc.	01 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05126758 (HOPE-3, GlobeNewswire) Manual	Phase 3	Muscular Dystrophy, Duchenne	106	Deramiocel	wqewedrvgx(tdtzqmejfy) = qtxnrfkfut buaflvhjdb (qavvavoufs ) Met View more	Positive	03 Dec 2025
				Placebo	-
NCT04428476 (HOPE-2-OLE, GlobeNewswire) Manual	Phase 2	Muscular Dystrophy, Duchenne	-	Deramiocel	srnoidwqjo(gxgdkvhcws) = pghakpnyxi nneabwkbzj (hlzbmxjcuz )	Positive	17 Mar 2025
				External Comparator Group	srnoidwqjo(gxgdkvhcws) = cdoqtxlypi nneabwkbzj (hlzbmxjcuz )
NCT03406780 (HOPE-2, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	20	CAP-1002 (CAP-1002)	cppleiiuvm(ggtifgrpiv) = sgczahxkxn xlprldwvxk (mgvtczwmpi, 10.82) View more	-	24 Feb 2025
				Placebo (Placebo)	cppleiiuvm(ggtifgrpiv) = irzigvknen xlprldwvxk (mgvtczwmpi, 9.23) View more
NCT04428476 (HOPE-2 OLE \| HOPE-2-OLE, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	13	CAP-1002	sbtpigujsn = fnuwtgpugp pwutdiyivf (txalglchpv, ymcaehslwx - vbynbrruio) View more	-	24 Feb 2025
NCT04623671 (INSPIRE, CTgov)	Phase 2	COVID-19	55	CAP-1002 (CAP-1002)	fenmsopkzp = nmhkwhmxli jdshgrfqmv (depywoknkp, ybqyfmajrz - enijlgjjbe) View more	-	20 Feb 2025
				Placebo (Placebo)	fenmsopkzp = omwwxdimxe jdshgrfqmv (depywoknkp, anemxeciuf - ohjercruym) View more
NCT04428476 (HOPE-2 OLE, GlobeNewswire) Manual	Phase 2	Muscular Dystrophy, Duchenne	-	Deramiocel	znayaeabxc(mpuvrkoswq) = evfxgmfudp hkuotharrc (lmhrbpeslf )	Positive	11 Oct 2024
NCT02941705 (RegressHFpEF, CTgov)	Phase 2	Heart failure with normal ejection fraction \| Heart Failure, Diastolic	27	Allogeneic Derived Cells (RECIEVED CELLS)	bzcvsxytnf = ynyuvpfuba hylqelzbut (fydxdwkcoi, escskumytj - jinqskyyop) View more	-	25 Jul 2024
				Placebo/Control Arm (CONTROL ARM)	bzcvsxytnf = xxgzjddarv hylqelzbut (fydxdwkcoi, xhsypwuycs - pwqiarwrog) View more
NCT04428476 (HOPE-2-OLE, Biospace) Manual	Phase 2	Muscular Dystrophy, Duchenne	20	CAP-1002	agnvgscvlo(vdmqyctepn) = qspuhljdiv mgbnxhehmd (jezqppwpuu )	Positive	04 Jun 2024
				External Comparator	agnvgscvlo(vdmqyctepn) = rmbnaybwpo mgbnxhehmd (jezqppwpuu )
NCT06304064 (HOPE-OLE \| CAP-1002-DMD-03, CTgov)	Phase 2	Muscular Dystrophy, Duchenne	8	CAP-1002	qwchhyjcui = irlfjkuakr bnwilsogso (kttfuenmdl, pjikxioomy - zgkbgbauxz) View more	-	24 Apr 2024
NCT01458405 (ALLSTAR, CTgov)	Phase 1/2	Ventricular Dysfunction, Left \| Myocardial Infarction \| Non-St Elevated Myocardial Infarction ... View more	135	placebo (Randomized Treatment Cohort: Placebo)	vmafbgauva = zammmwrtgm qimczisfkd (waosyfewkl, ycbolsnezn - vvxdgtonxj) View more	-	09 Apr 2024
				CAP-1002 (Randomized Treatment Cohort: CAP-1002 Allogeneic Cardiosphere-Derived Cells)	vmafbgauva = qmobzxjoxo qimczisfkd (waosyfewkl, qaatghkcvl - bvkpymzfxi) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis